Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed and validated a UV spectrophotometric method for accurately estimating Minoxidil in tablet form, showing linearity across concentrations from 1-6µg/ml.

This study found that compounded minoxidil solutions in a propylene glycol-free and alcohol-reduced foam remained stable for 180 days, meeting United States Pharmacopeia standards for strength, pH, and antimicrobial effectiveness.

In this randomized controlled trial, oral minoxidil at 2.5 mg daily was more effective than topical minoxidil for increasing hair thickness, counts, and density in men with androgenetic alopecia, demonstrating more significant improvements and better compliance over six months.

This study developed and validated a reverse phase liquid chromatography method to accurately and reliably measure Minoxidil and Finasteride in bulk and marketed formulations.

This study developed and validated a simple, precise, and cost-effective UV spectrophotometric method for quantifying Minoxidil in bulk and pharmaceutical forms, reporting high accuracy with recovery rates between 99.57% and 100.55%, and a correlation coefficient of 0.9993.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

In this study, a unique form of chronic superficial pyoderma gangrenosum with verrucous and ulcerative lesions was reported to heal without systemic corticosteroids in most patients.

This article addresses diffuse pattern essential syphilitic alopecia as an unusual form of secondary syphilis but provides no new clinical findings.

This review outlines current treatments for androgenetic alopecia, highlighting the efficacy and side effects of FDA-approved options like minoxidil and finasteride, and emphasizes the necessity of long-term use and careful patient collaboration to avoid adverse reactions.

This guideline summarizes evidence-based and expert-based recommendations for treating androgenetic alopecia, adapted by an Italian expert group in alignment with Italian pharmacological policies.

This article describes the diagnostic process and rewards of evaluating female hair loss but reports no new clinical findings.

Certain skin drugs and topical agents, including some natural extracts and fragrances, can cause allergic reactions. Some hair dyes and extensions, as well as minoxidil, a hair growth treatment, can also cause allergies. Botulinum toxin A can effectively reduce sweat but may have temporary side effects.

This study reported that optimized transfersomes and their gel form significantly improved transdermal delivery and hair growth promotion of minoxidil in C57BL/6 mice compared to commercial formulations.

This study found that arylsulfatase enzymes in hair follicles can convert the active form of minoxidil back to its inactive form, potentially affecting its effectiveness in treating androgenetic alopecia.

This study found that minoxidil is bioactivated through sulfation by the phenol-sulfating form of phenol sulfotransferase in human liver.

This literature review suggests that oral minoxidil may improve tolerability compared to its topical form for treating androgenetic alopecia, although individual treatment plans are necessary due to differing side effects and response patterns.

This study developed a rapid and accurate spectrophotometric method using diazotized sulfanilic acid to measure minoxidil in both pharmaceutical formulations and pure form, demonstrating high precision and linearity within a concentration range of 5-40 μg/ml.

This study reported that polymeric nanofibers containing minoxidil sulphate showed effective encapsulation and stability, with minimal concentration loss over six months, making them potentially ideal for delivering this unstable drug in a more visually appealing and easier-to-apply form.

This randomized controlled trial investigated the impact of a placebo on non-vellus hair count in individuals with androgenetic alopecia, a common form of hair loss affecting both men and women, but results were not reported.

This study describes the development of a minoxidil gel using the copolymer Sepineo P 600, showing improved spreadability, occlusivity, adhesiveness, and stability compared to minoxidil lotion, without causing skin corrosion, making it a potentially more effective treatment form for alopecia areata.

This source discusses androgenetic alopecia, noting that male patients may transition from topical minoxidil to its systemic form or from finasteride to dutasteride for potentially better results, while female patients might require extensive lab testing to identify hyperandrogenism due to environmental triggers.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

Oral minoxidil may improve hair loss in men and women, but has some side effects.

Combining topical finasteride with minoxidil significantly improves hair density in treating hair loss.

This study reviews the effectiveness, viability, and safety of minoxidil and finasteride in treating androgenetic alopecia in women, aiming to provide insights for better management of this condition based on bibliographic comparisons.

This paper describes androgenic alopecia as a hereditary form of hair loss influenced by androgens, outlining its diagnosis, treatment options like minoxidil and finasteride, and the importance of psychological support due to its impact on quality of life.

This study found that the gel form of substance Y led to more hair follicles in the growth phase than 2% minoxidil solution when applied for alopecia treatment in mice.

This study found that loose anagen hair syndrome is a common form of alopecia in young girls, typically presenting with thin, sparse hair and usually confirmed by a hair-pull test.

This abstract introduces androgenic alopecia as the most common form of non-cicatricial alopecia, which predominantly affects men but also has a significant occurrence in women; however, specific research results or conclusions about treatments or mechanisms are not reported in the summary.